TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23461916

Group type: EXPERIMENTAL
Intervention: Driven gait orthosis (Lokomat)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Gait training along a rail inside a hydrotherapy tank
Number of subjects: 14
Study: 20522698

Group type: EXPERIMENTAL
Intervention: Clinically integrated e‐learning EBM course
Number of subjects: 237

Group type: COMPARATOR
Intervention: Lecture‐based course
Number of subjects: 237
Study: 18318455

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16824242

Group type: EXPERIMENTAL
Intervention: MCT/LCT‐propofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: LCT‐propofol
Number of subjects: 120
Study: 12796139

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10853456

Group type: EXPERIMENTAL
Intervention: New endocrine agents for receptor-positive patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trials
Number of subjects: 0
Study: 8771302

Group type: EXPERIMENTAL
Intervention: Prostheses oriented in a perpendicular position with respect to the ventricular septum
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prostheses oriented in a parallel position with respect to the ventricular septum
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both orientations
Number of subjects: 90
Study: 1617601

Group type: EXPERIMENTAL
Intervention: Reminder plastic credit card
Number of subjects: 220

Group type: COMPARATOR
Intervention: Traditional encouragement/reminders (control group)
Number of subjects: 220
Study: 6383779

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (Spofa)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Diluran Spofa)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (before therapy)
Number of subjects: 23
Study: 31063024

Group type: EXPERIMENTAL
Intervention: Edmonton Symptom Assessment System (ESAS)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Quality of life at the end of life (QUAL‐E)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Correspondence between ESAS and QUAL‐E
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Pain and/or tiredness
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Appetite
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Probability of rating a symptom as most severe and most bothersome
Number of subjects: 386
Study: 29853984

Group type: EXPERIMENTAL
Intervention: Walking on a treadmill at a regular speed of 5 km/h
Number of subjects: 16
Study: 26743397

Group type: EXPERIMENTAL
Intervention: Nutraceutical diet (ND group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard diet (SD group)
Number of subjects: 30
Study: 24434584

Group type: EXPERIMENTAL
Intervention: Enriched biscuits+enriched juice (8g β‐glucan)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enriched biscuits+juice (4g β‐glucan)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biscuits+enriched juice (4g β‐glucan)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biscuits+juice (0g β‐glucan)
Number of subjects: 30
Study: 23234087

Group type: EXPERIMENTAL
Intervention: Active observation of dance therapy (30 min. live session)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Passive listening to pre-recorded music (30 min.)
Number of subjects: 100
Study: 19572858

Group type: EXPERIMENTAL
Intervention: Contact mapping
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Noncontact mapping
Number of subjects: 40
Study: 17212718

Group type: EXPERIMENTAL
Intervention: Immunate S/D
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prophylactic regimen with Immunate S/D
Number of subjects: 56

Group type: COMPARATOR
Intervention: Immunate
Number of subjects: 56
Study: 16097636

Group type: EXPERIMENTAL
Intervention: Deep inspiration breath‐hold SPECT (BrST)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional free breathing (FB) method
Number of subjects: 15
Study: 12386350

Group type: EXPERIMENTAL
Intervention: NovaSure system
Number of subjects: 265

Group type: COMPARATOR
Intervention: Wire loop resection and rollerball ablation
Number of subjects: 265
Study: 9919039

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Interclean, model ID2
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADA‐approved waxed dental floss
Number of subjects: 0
Study: 8571922

Group type: EXPERIMENTAL
Intervention: Danggui‐Nian‐Tong‐Tang (DGNTT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro study in rats with DGNTT
Number of subjects: 0
Study: 2210795

Group type: EXPERIMENTAL
Intervention: Preparation I (modified allergenic extract)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preparation II (standard semi-depot extract)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 20
Study: 530804

Group type: EXPERIMENTAL
Intervention: Blocked design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised design
Number of subjects: 0
Study: 31397126

Group type: EXPERIMENTAL
Intervention: Auricular-point pressure combined with personalized music therapy
Number of subjects: 1000
Study: 27893933

Group type: EXPERIMENTAL
Intervention: Cancer and Treatment Distress (CTXD) measure before transplantation and at 100 days and 180 days after HCT
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Medical Outcomes Study Short Form‐36 (SF‐36) Mental Health subscale
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Pretransplantation CTXD
Number of subjects: 701
Study: 26498479

Group type: EXPERIMENTAL
Intervention: Peer role play (RP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standardized patients (SP)
Number of subjects: 69
Study: 23375209

Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCAA)
Number of subjects: 1872

Group type: EXPERIMENTAL
Intervention: Various metabolites
Number of subjects: 1872

Group type: EXPERIMENTAL
Intervention: C4/Ci4, C3, C5 acylcarnitines
Number of subjects: 1872

Group type: EXPERIMENTAL
Intervention: Amino acids
Number of subjects: 1872
Study: 20978485

Group type: EXPERIMENTAL
Intervention: EMS practice (study group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no EMS practice)
Number of subjects: 16
Study: 19143016

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser + APF application
Number of subjects: 33

Group type: COMPARATOR
Intervention: APF application (control group)
Number of subjects: 33
Study: 17516149

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 299

Group type: COMPARATOR
Intervention: Injectable insulin
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Current treatment burden
Number of subjects: 299
Study: 15026583

Group type: EXPERIMENTAL
Intervention: 10 mg leflunomide
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: 20 mg leflunomide
Number of subjects: 402
Study: 11787753

Group type: EXPERIMENTAL
Intervention: Agricultural work activities
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Demographic variations in work involvement
Number of subjects: 1138
Study: 9601481

Group type: EXPERIMENTAL
Intervention: Compliant balloons (polyolefin copolymer)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-compliant balloons (polyethylene terapthelate)
Number of subjects: 200
Study: 8022532

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 23
Study: 2510283

Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1106966

Group type: EXPERIMENTAL
Intervention: dextro-amphetamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 48

Group type: COMPARATOR
Intervention: racemic-amphetamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: dextro-amphetamine and racemic-amphetamine
Number of subjects: 48
Study: 31461581

Group type: EXPERIMENTAL
Intervention: 14 days of twice‐daily 16.5% Manuka honey + 1.3 mg/mL methylglyoxal sinonasal rinses and concurrent 10 days of placebo tablets (MH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 14 days of twice‐daily saline sinonasal rinses and concurrent 10 days of culture‐directed antibiotic therapy (CON)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Safety observations including the University of Pennsylvania Smell Identification Test (UPSIT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Efficacy assessed using Lund‐Kennedy scores (LKSs), visual analog scale (VAS), and 22‐item Sino‐Nasal Outcome Test (SNOT‐22)
Number of subjects: 25
Study: 28886163

Group type: EXPERIMENTAL
Intervention: Bespoke mental health training package
Number of subjects: 249

Group type: COMPARATOR
Intervention: Routine training
Number of subjects: 249
Study: 25599305

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine, 100 μg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine, 2 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both treatments (clonidine and adenosine)
Number of subjects: 22
Study: 23910171

Group type: EXPERIMENTAL
Intervention: Induction of labour (N=321)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Expectant management (N=329)
Number of subjects: 650
Study: 21152931

Group type: EXPERIMENTAL
Intervention: Continuous exercise (CONT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Interval exercise (INT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Recovery (REC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Stroop Color Word Test (SCWT)
Number of subjects: 11
Study: 20029100

Group type: EXPERIMENTAL
Intervention: SAQ training
Number of subjects: 20
Study: 16978994

Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy based on risk stratification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional centers of excellence for care of patients with acute ischemic heart disease
Number of subjects: 0
Study: 12629445

Group type: EXPERIMENTAL
Intervention: Losartan therapy
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study: 11003427

Group type: EXPERIMENTAL
Intervention: Injection technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Implantation technique
Number of subjects: 50
Study: 9323618

Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (30 seconds after birth)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Immediate umbilical cord clamping
Number of subjects: 46
Study: 8259718

Group type: EXPERIMENTAL
Intervention: Fish oil fatty acids supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-vegetarians)
Number of subjects: 0
Study: 3002786

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg kg‐1 and atropine 0.2‐0.4 mg i.m.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Papaveretum 0.4 mg kg‐1 and hyoscine 0.008 mg kg‐1 i.m.
Number of subjects: 16
Study: 31274718

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Regional Anesthesia (RA)
Number of subjects: 88
Study: 29017017

Group type: EXPERIMENTAL
Intervention: Cluster sets (CRT; n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional sets (TRT; n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON; n = 10)
Number of subjects: 30
Study: 26850709

Group type: EXPERIMENTAL
Intervention: Bionic pancreas
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (conventional insulin pump therapy)
Number of subjects: 19
Study: 25285831

Group type: EXPERIMENTAL
Intervention: Contractor safety climate
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Coworker safety climate
Number of subjects: 1725
Study: 21865211

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment (monotherapy in AFFIRM)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment (in combination with interferon β‐1a in SENTINEL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment (both alone and in combination with IFNβ)
Number of subjects: 2
Study: 20345732

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU, Nebido(®)), 1,000 mg injected on day 1, followed by injections after 6 weeks and 18 weeks
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU, Nebido(®))
Number of subjects: 133
Study: 18655991

Group type: EXPERIMENTAL
Intervention: Moxifloxacin instilled 4 times a day 1 day before surgery plus 1 drop 2 hours before surgery (Group A)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Moxifloxacin instilled 2 hours before surgery and then every 15 minutes for 1 hour (Group B)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 156
Study: 11684917

Group type: EXPERIMENTAL
Intervention: Aspirin, beta blockers, and angiotensin-converting enzyme inhibitors
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (thrombolysis and primary angioplasty)
Number of subjects: 1
Study: 9930483

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (n = 15)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (n = 16)
Number of subjects: 48
Study: 8040664

Group type: EXPERIMENTAL
Intervention: Gemcitabine at a dose of 1,000 mg/m2
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Gemcitabine at a dose of 1,250 mg/m2
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 84
Study: 3051874

Group type: EXPERIMENTAL
Intervention: Prostaglandin vaginal suppositories (PGE2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 30868734

Group type: EXPERIMENTAL
Intervention: DACC-coated dressing
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control dressing
Number of subjects: 144
Study: 28974069

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 25928356

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Secondary intention wound healing (control)
Number of subjects: 40
Study: 22699800

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 64

Group type: COMPARATOR
Intervention: Photofrin-PDT
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both ALA-PDT and Photofrin-PDT
Number of subjects: 64
Study: 21806297

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 239
Study: 19170659

Group type: EXPERIMENTAL
Intervention: Early surfactant treatment (31 +/- 19 min)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Late surfactant treatment (202 +/- 80 min)
Number of subjects: 185
Study: 16708528

Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device (ITD) during head-up tilt (HUT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham control (no ITD) during head-up tilt (HUT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device (ITD) in subgroup with < 20% reduction in SV
Number of subjects: 19
Study: 15566454

Group type: EXPERIMENTAL
Intervention: 100 mg elemental iron daily (n=55)
Number of subjects: 111

Group type: COMPARATOR
Intervention: 200 mg elemental iron weekly (n=56)
Number of subjects: 111
Study: 11220419

Group type: EXPERIMENTAL
Intervention: Fixed ventilation group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Constant CO2 group
Number of subjects: 24
Study: 9283506

Group type: EXPERIMENTAL
Intervention: 65 mg of methadone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 12 mg of buprenorphine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 20 mg of methadone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 4 mg of buprenorphine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Lower doses of buprenorphine and methadone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 116
Study: 8285455

Group type: EXPERIMENTAL
Intervention: Hyperactive group (n = 39)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Depressed Hyperactive Group (DHG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Non-Depressed Hyperactive Group (HG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HG group
Number of subjects: 39
Study: 31808717

Group type: EXPERIMENTAL
Intervention: Incongruent text messages (mismatching regulatory focus)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Congruent text messages (matching regulatory focus)
Number of subjects: 279

Group type: COMPARATOR
Intervention: General health messages (control group)
Number of subjects: 279
Study: 31176611

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 66
Study: 28942217

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Switching from olanzapine to risperidone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Risperidone and Olanzapine
Number of subjects: 107
Study: 26375690

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 0
Study: 24200186

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral feeding
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both NG and oral feeding
Number of subjects: 50
Study: 21611944

Group type: EXPERIMENTAL
Intervention: Bipolar electrocoagulation (BEC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 30
Study: 19147399

Group type: EXPERIMENTAL
Intervention: autotitrating pressure relief CPAP (PR‐APAP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: autotitrating CPAP (APAP)
Number of subjects: 11
Study: 16689375

Group type: EXPERIMENTAL
Intervention: Beta-blocker carvedilol (5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker carvedilol (20 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker carvedilol (under 2.5 mg/day)
Number of subjects: 0
Study: 15220768

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 microg/ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ephedrine 3 mg/ml
Number of subjects: 60
Study: 11427407

Group type: EXPERIMENTAL
Intervention: Body mass index < or =20.3 in men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body mass index < or =18.5 in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat mass < or =6% in men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat mass < or =18% in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm muscle circumference
Number of subjects: 0
Study: 9241342

Group type: EXPERIMENTAL
Intervention: 27-gauge Whitacre needle
Number of subjects: 200

Group type: COMPARATOR
Intervention: 27-gauge Quincke needle
Number of subjects: 200
Study: 8306010

Group type: EXPERIMENTAL
Intervention: IVF treatment (1 or more cycles)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control group (awaiting IVF treatment)
Number of subjects: 399
Study: 3734775

Group type: EXPERIMENTAL
Intervention: Indalpine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 42
Study: 31228228

Group type: EXPERIMENTAL
Intervention: Routine use of automatically calculated birthweight centiles (2015)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Adherent care to the guideline (2015)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-adherent care to the guideline (2011)
Number of subjects: 400
Study: 30342464

Group type: EXPERIMENTAL
Intervention: Home based, low intensity physical exercise program
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 27842499

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of remifentanil (0.3‐μg/kg/min for 5 min followed by 0.1‐μg/kg/min)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Two bolus injections of remifentanil (first bolus of 0.4 μg/kg and second bolus of 0.6 μg/kg after 3 min) and 0.1 μg/kg/min remifentanil
Number of subjects: 107
Study: 24447332

Group type: EXPERIMENTAL
Intervention: Elevated TIMP-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated MMP-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated MMP-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cases (resistant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 22472914

Group type: EXPERIMENTAL
Intervention: Bar graphs
Number of subjects: 106

Group type: COMPARATOR
Intervention: Tables
Number of subjects: 106
Study: 20386122

Group type: EXPERIMENTAL
Intervention: Treatment protocol (4RM parallel back half-squat)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control protocol (no 4RM back-squat)
Number of subjects: 12
Study: 18247155

Group type: EXPERIMENTAL
Intervention: Mailed reminder
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Short telephonic reminder
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no reminder)
Number of subjects: 320
Study: 16641287

Group type: EXPERIMENTAL
Intervention: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 with biovector
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 without biovector
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccine with 15 microg hemagglutinin and MF59 adjuvant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group (saline solution)
Number of subjects: 100
Study: 14710766

Group type: EXPERIMENTAL
Intervention: Test group (bilaminar surgical technique with modified connective tissue graft)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (bilaminar surgical technique with standard connective tissue graft)
Number of subjects: 15
Study: 10720584

Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112